Generated by AI
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases associated with misfolded proteins. Its research and development activities address conditions including Alzheimer’s disease, Parkinson’s disease, and selected neuro-orphan disorders. The company uses its proprietary SupraAntigen and Morphomer platforms to discover and design therapeutic and diagnostic products, including antibodies, small molecules, vaccines, and imaging agents. These technologies are intended to selectively target disease-related proteins such as amyloid, tau, and alpha-synuclein, supporting applications in disease prevention, diagnosis, monitoring, and treatment. AC Immune SA operates across the biotechnology and pharmaceutical sectors, combining molecular research, clinical development, biomarker discovery, and diagnostic innovation. Its work contributes to the development of disease-modifying approaches in areas where protein aggregation plays a central role, while its partnerships and product programs connect the company with global pharmaceutical, healthcare, and clinical research markets. Headquartered in Lausanne, Switzerland, AC Immune SA represents a specialized participant in the biopharmaceutical market for neurodegenerative disease.
WebsiteBuilding B
Lausanne, 1015
Switzerland
The latest articles about ACIU.
AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson’s disease. The placebo-controlled study enrolled 34 participants, with 25 receiving ACI-7104.056 and ni
Summary of Aug 11's posts. Generated by AI.
Summary of Dec 11's posts. Generated by AI.
Summary of May 13's posts. Generated by AI.
Investors talking about ACIU also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.